CEO Albert Bourla is set to meet with activist investor Starboard Value amid growing pressure to revitalize the ...

Pfizer CEO Albert Bourla plans to meet activist investor Starboard Value, the Financial Times reported on Tuesday, citing ...

Since 2011, Starboard Value's Jeff Smith has extracted board seats and profits from corporate America — by force if necessary ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...

Citing people familiar with the matter, The Journal reported that Starboard approached former Pfizer CEO Ian Read and CFO ...

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...

Pfizer CEO is set to meet with activist investor Starboard Value after the investor acquired a $1 billion stake in the ...

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00. The ...

Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...

Pfizer Inc. closed $5.14 below its 52-week high ($34.11), which the company achieved on October 3rd. Supported by world-class ...

Pfizer is also discontinuing all studies and access programs related to the treatment based on the available clinical data, ...